Clinical trials
HIV-1-infection clinical trials
Below are recruiting hiv-1-infection clinical trials, each written for real people, not researchers. We’re tracking 88 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07698600RecruitingPhase 1
Safety test of a new HIV vaccine in adults with or without HIV
This study tests a new RNA-based vaccine called BNT168 to see if it is safe and how the body responds to it. It is for healthy adults with or without HIV, and those with HIV will pause their regular treatment for a while during the study.
Houston, TexasAges 18–50 - NCT07708727RecruitingPhase 2/Phase 3
Injectable HIV treatment vs daily pill for new patients
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
Ft. Pierce, FloridaAges 18 years+ - NCT07645287RecruitingPhase 2
New HIV Combination Therapy for People on Biktarvy
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Beverly Hills, CaliforniaAges 18 years+ - NCT06203132RecruitingPhase 3
Doravirine vs Dolutegravir for first-time HIV treatment
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Nova Iguaçu, Rio de JaneiroAges 18 years+ - NCT05143307Enrolling by invitationPhase 1
Follow-up study for adults who received EBT-101 for HIV
This study checks how adults are doing long-term after receiving an HIV treatment called EBT-101 in an earlier study. It helps researchers understand safety and longer-term effects over time.
San Francisco, CaliforniaAges 18 years+ - NCT04553081RecruitingPhase 4
Switching HIV treatment: 2-drug versus 3-drug plan
This trial compares two different HIV treatment plans: keeping you on a 2-drug regimen versus switching to a 3-drug regimen. It’s designed for people whose HIV is well controlled and looks at whether the switch is safe and effective.
GhentAges 18 years+ - NCT00796263RecruitingPhase 3
Test HIV medicines for people with new or long-term HIV
This Phase 3 study looks at antiretroviral treatment (HIV medicines) for adults with either recent (acute) or long-term (chronic) HIV. It’s designed to see how well and safely ongoing HIV treatment works, and it may help you get structured care and monitoring.
BangkokAges 18 years+ - NCT06928090Enrolling by invitation
HIV trial testing two-med combo for first-time treatment
This trial studies a two-drug pill (DTG/3TC) for people who have never taken HIV medication before. It aims to see if this simpler treatment is effective and safe for controlling HIV-1.
DaejeonAges 19 years+ - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT06337032RecruitingPhase 4
Continued access to HIV treatment for children and teens
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
Buenos AiresAges 1 month+ - NCT05660980RecruitingPhase 1/Phase 2
Oral and monthly shots for HIV control in children
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Atlanta, GeorgiaAges 2–11 - NCT06640192RecruitingPhase 2
High-dose HIV drugs to clear hidden virus
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Madrid, MadridAges 18–60 - NCT07725042Recruiting
HIV infection study in Hong Kong for newly diagnosed adults
This study looks at people newly diagnosed with HIV in Hong Kong. It aims to understand patterns of infection to improve care.
North PointAges 18 years+ - NCT06602622RecruitingPhase 4
Weight change study for people with HIV switching to DOR/3TC/TDF
This study tests whether switching your HIV medication to a combination called DOR/3TC/TDF can help with weight changes that started after taking another type of HIV drug (integrase inhibitor). It is for people who have gained weight unintentionally and want to see if a different medication helps manage it.
Mexico City, AzcapotzalcoAges 18–80 - NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Seattle, WashingtonAges 18–65 - NCT06631365RecruitingPhase 2
PrEP on demand: a pilot study for men who have sex with men
This study tests a '2-1-1' on-demand PrEP strategy for cisgender men who have sex with men. It aims to see if taking PrEP only around the time of sex is safe and effective. If you are interested in starting or currently taking PrEP this way, you may be eligible.
San Francisco, CaliforniaAges 18 years+ - NCT06648629Recruiting
Counseling to help HIV patients who drink too much
This study tests a counseling approach called Acceptance and Commitment Therapy (ACT) to help people living with HIV who drink at unhealthy levels reduce their drinking. If you're on HIV treatment and drink more than recommended, this program may help you build healthier habits.
Syracuse, New YorkAges 18 years+ - NCT06646562RecruitingPhase 4
Long-acting injectable HIV meds for adults 60 and older
This study tests whether two long-acting injectable HIV medications (cabotegravir and rilpivirine) can keep the virus under control in people aged 60 and older. It aims to offer a convenient alternative to daily pills for older adults with HIV.
Elche, AlicanteAges 60 years+ - NCT06880380RecruitingPhase 1
CAR-T cell therapy for functional HIV cure
This trial tests whether CAR-T cells can help control HIV without daily antivirals. It is for people with well-controlled HIV who want to explore a potential functional cure.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05668026RecruitingPhase 1/Phase 2
Venetoclax to shrink HIV reservoir in people on stable ART
This Phase 1/2 study tests whether venetoclax can help reduce the “HIV reservoir,” which is a hidden group of HIV-infected cells, while you stay on your usual HIV treatment. It also looks at whether the drug helps these infected cells die off in a controlled, safe way.
AarhusAges 18–65 - NCT05719441RecruitingPhase 2
Antibodies plus early HIV treatment to try for HIV remission
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
Birmingham, AlabamaAges 18–70 - NCT06890988Recruiting
Dental team study to help end HIV epidemic
This trial tests if training dental teams (dentists, hygienists, assistants, navigators) can help end the HIV epidemic by offering HIV testing and prevention in dental visits. You may be able to join if you work in a dental practice that is part of this study.
New York, New YorkAges 18 years+ - NCT06902142Recruiting
HIV treatment study with Bictegravir medication monitoring
This study looks at how well HIV-1 patients take their medication (bictegravir/emtricitabine/tenofovir) and how that relates to how well the virus is controlled. It uses a special pill bottle cap that records when the bottle is opened, so the research team can see if the medicine is being taken as prescribed.
CaenAges 18 years+
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
HIV-1-infection trials by city
Studies with a site in or near these metro areas.
HIV-1-infection trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hiv-1-infection?
- Yes. Clin2 currently lists 88 recruiting hiv-1-infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1-infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1-infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.